| Genentech, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120135008 | METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN - Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided. | 05-31-2012 |
| 20120128585 | Method of Diagnosing the presence of a tumor in a mammal by assessing CDO expression level - The present invention provides for a method of using BOC/CDO hedgehog antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such as hair growth, neural stem cell differentiation, chondrogenesis and osteogenesis, lung surfactant production, formation of lamellated bodies in lung cells. | 05-24-2012 |
| 20120123122 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND - The present invention relates to a method for manufacturing a boronic acid ester compound, characterized by reacting an aryl halide compound and a diboron ester compound in the presence of a nitrogen-containing organic base, a nickel catalyst, a phosphine compound and a solvent. According to the manufacturing method of the present invention, even if a nickel catalyst is used as the catalyst, a desired boronic acid ester compound can be obtained in a sufficiently high yield. Furthermore, even if aryl chloride or aryl bromide having relatively low price and low reactivity, was used as the aryl halide compound, a desired boronic acid ester compound can be obtained in a sufficiently high yield. | 05-17-2012 |
| 20120114644 | ANTAGONIST ANTI-NOTCH3 ANTIBODIES AND THEIR USE IN THE PREVENTION AND TREATMENT OF NOTCH3-RELATED DISEASES - The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders. | 05-10-2012 |
| 20120107391 | THERAPY OF PLATINUM-RESISTANT CANCER - The present invention concerns a method for treating platinum-resistant, ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma with the combination of a HER2 antibody that effectively inhibits HER dimerization as well as gemcitabine. | 05-03-2012 |
| 20120100562 | METHODS AND COMPOSITIONS FOR MODULATING THE WNT PATHWAY - The invention provides methods and compositions for modulating the Wnt signaling pathway, in particular by interfering with binding of Dkk1 or SOST with LRP5 and/or LRP6. | 04-26-2012 |
| 20120089541 | BIOMARKERS AND METHODS OF TREATMENT - The present invention concerns cancer biomarkers. In particular, the invention concerns c-met as biomarkers for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto. | 04-12-2012 |
| 20120082663 | ANTI-CMET ANTAGONISTS - The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies. | 04-05-2012 |
| 20120082662 | ANTI-CMET ANTAGONISTS - The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies. | 04-05-2012 |
| 20120077740 | Methods for making Apo-2 Ligand using divalent metal ions - Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis. | 03-29-2012 |
| 20120076785 | METHOD FOR INHIBITING NEURODEGENERATION - Methods for screening for compounds that inhibit neurodegeneration are presented. Shedding of APP can be a useful marker for neurodegeneration and compounds that inhibit shedding of APP are useful as inhibitors of neurodegeneration. Such compounds may be useful in treatment and/or prevention of various neurological diseases, disorders and neuronal damage and may enhance growth, regeneration or survival of mammalian neuronal cells or tissue. | 03-29-2012 |
| 20120076783 | REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS - The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations. | 03-29-2012 |
| 20120070428 | TREATMENT OF VASCULARIZED PIGMENT EPITHELIAL DETACHMENT WITH ANTI-VEGF THERAPY - Methods for treating vascularized pigment epithelial detachment using anti-VEGF agents are disclosed. | 03-22-2012 |
| 20120064086 | HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS - The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein. | 03-15-2012 |
| 20120058953 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS - The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same. | 03-08-2012 |
| 20120045448 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS - Compounds of the disclosure provide compositions, which are effective for prophylaxis and treatment of diseases or disorders, such as cell-proliferation, angiogenesis, or apoptosis mediated diseases. The disclosure encompasses compounds, analogs, prodrugs, metabolites, and pharmaceutically acceptable salts thereof, pharmaceutical compositions, and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer, tumors, and like conditions. The disclosure also provides therapeutic methods including the administration of an effective amount of a compound of the disclosure. | 02-23-2012 |
| 20120045390 | Composition and Methods for the Diagnosis and Treatment of Tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 02-23-2012 |
| 20120042400 | RTD RECEPTOR - Novel polypeptides, designated RTD, which are capable of binding Apo-2 ligand are provided. Compositions including RTD chimeras, nucleic acid encoding RTD, and antibodies to RTD are also provided. | 02-16-2012 |
| 20120041176 | UCP4 - The present invention is directed to novel polypeptides having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. | 02-16-2012 |
| 20120039893 | MUTANT SMOOTHENED AND METHODS OF USING THE SAME - The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, we describe a mutation in the serpentine receptor, Smoothened (SMO), which results in resistance to a Hedgehog (Hh) pathway inhibitor in medulloblastoma. A single amino acid substitution in a conserved glutamic acid residue of SMO maintains Hh signaling, but results in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. The invention provides screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance. | 02-16-2012 |
| 20120034609 | GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN EGFR ANTAGONIST CANCER THERAPY - The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody. | 02-09-2012 |
| 20120028829 | ANTI-HEDGEHOG ANTIBODIES - The invention relates to anti-hedgehog antibodies, their use in the detection of hedgehog expression in tissue, and to the use of such detection in the treatment of cancer. | 02-02-2012 |
| 20120022043 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS - The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R | 01-26-2012 |
| 20120015974 | IMIDAZOPYRIDINE INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: | 01-19-2012 |
| 20120010191 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE - Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 01-12-2012 |
| 20120009185 | METHOD FOR TREATING AGE-RELATED MACULAR DEGENERATION - A method is provided for administering to a mammal suffering from, or at risk for, age-related macular degeneration. | 01-12-2012 |
| 20120009182 | IMMUNOGLOBULIN VARIANTS WITH ALTERED BINDING TO PROTEIN A - Variant immunoglobulins with one or more amino acid modifications in the VH region that have altered binding to | 01-12-2012 |
| 20120003208 | COMPOSITIONS AND METHODS FOR MODULATING VASCULAR DEVELOPMENT - The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided. | 01-05-2012 |
| 20110319327 | Polypeptides Homologous to VEGF and BMP1 - The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue. | 12-29-2011 |
| 20110311534 | WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS - The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer. | 12-22-2011 |
| 20110311524 | Inhibitors of Angiopoietin-Like 4 Protein, Combinations, and Their Use - Modulators of angiopoietin-like 4 protein are provided along with methods for their use in the treatment of diseases and pathological conditions. Combinations of ANGPTL4 antagonists and other therapeutics, e.g., anti-cancer agents, and methods of their use in the treatment of mammals susceptible to or diagnosed with cancer, or with relapse tumor growth or relapse cancer cell growth are also provided. | 12-22-2011 |
| 20110311520 | METHODS FOR TREATMENT OF ALLERGIC ASTHMA - Methods of treatment of allergic asthma with IgE antagonists, including anti-IgE antibodies, IgE variants, peptide antagonists, peptidomimetics and other small molecules, are described. | 12-22-2011 |
| 20110301141 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS - Compounds of the formula I: | 12-08-2011 |
| 20110300146 | ANTI-CMET ANTAGONISTS | 12-08-2011 |
| 20110300136 | THERAPY OF AUTOIMMUNE DISEASE IN A PATIENT WITH AN INADEQUATE RESPONSE TO A TNF-ALPHA INHIBITOR - The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor. | 12-08-2011 |
| 20110294990 | Refolding of Recombinant Proteins - Processes are provided for recovering and purifying refolded recombinant proteins produced in heterologous host cells, which includes the step of refolding the protein in a high pH buffer. | 12-01-2011 |
| 20110293632 | POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION - The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof. | 12-01-2011 |
| 20110287024 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS - The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization. | 11-24-2011 |
| 20110287009 | Production of Heteromultimeric Proteins - Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies. | 11-24-2011 |
| 20110287003 | TREATMENT METHODS - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer. | 11-24-2011 |
| 20110280870 | HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF - Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided. | 11-17-2011 |
| 20110269696 | INHIBITORS OF IAPS - The invention provides novel compounds that are inhibitors of IAPs having the general formula: wherein X | 11-03-2011 |
| 20110268727 | ANTI-INTERFERON-ALPHA ANTIBODIES - The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE). | 11-03-2011 |
| 20110262465 | PROSTATE STEM CELLS AND USES THEREOF - Prostate stem cells and prostate cancer stem cells and their use in treating prostate cancer and regenerating prostate tissue are disclosed. | 10-27-2011 |
| 20110262452 | ANTI-HEPSIN ANTIBODIES AND METHODS USING SAME - The invention provides hepsin antibodies, and compositions comprising and methods of using these antibodies. | 10-27-2011 |
| 20110262436 | TREATMENT METHOD - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer. | 10-27-2011 |
| 20110256150 | Modulation of Axon Degeneration - The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons. | 10-20-2011 |
| 20110256146 | NEUROPILIN ANTAGONISTS - Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications. | 10-20-2011 |
| 20110256133 | ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE - The invention provides anti-polyubiquitin antibodies and methods of using the same. | 10-20-2011 |
| 20110256127 | ANTI-LRP6 ANTIBODIES - The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms. | 10-20-2011 |
| 20110251181 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS - Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I). | 10-13-2011 |
| 20110246399 | PREDICTING RESPONSE TO A HER INHIBITOR - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. | 10-06-2011 |
| 20110245230 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. | 10-06-2011 |
| 20110245185 | APO-2 ligand/trail formulations - The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as well as devices and kits containing such formulations are also provided. | 10-06-2011 |
| 20110245103 | PREDICTING RESPONSE TO A HER INHIBITOR - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. | 10-06-2011 |
| 20110237779 | CDR-REPAIRED ANTIBODIES - The present application concerns restoring antigen binding during humanization of antibodies through the selection of repaired hypervariable regions rather than through framework changes. | 09-29-2011 |
| 20110230408 | HUMAN GROWTH HORMONE AQUEOUS FORMULATION - A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations. | 09-22-2011 |
| 20110226650 | ANTIBODY FORMULATION - The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation. | 09-22-2011 |
| 20110223619 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE - Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 09-15-2011 |
| 20110218211 | AZAINDOLE INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: I wherein X | 09-08-2011 |
| 20110208673 | ANTIBODIES TO LYMPHOTOXIN-ALPHA - The invention provides various antibodies that bind to lymphotoxin-α, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies. | 08-25-2011 |
| 20110207912 | FGF-19 NUCLEIC ACIDS - The present invention is directed to novel polypeptides having homology to the PRO533 protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis and/or autocrine signaling. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, and may act of predictors of the prognosis of tumor treatment. Furthermore, the compounds, compositions including antagonists and methods of the present invention are further expected to have therapeutic effect upon conditions characterized by FgF-19 modulation. | 08-25-2011 |
| 20110206704 | Methods and compositions for modulating hepatocyte growth factor activator - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of hepatocyte growth factor activator function, and the identification and uses of said modulators. | 08-25-2011 |
| 20110206702 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 08-25-2011 |
| 20110206675 | ANTI-NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF NOTCH3-RELATED DISEASES - The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders. | 08-25-2011 |
| 20110206663 | Anti-Interferon-Alpha Antibodies - The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE). | 08-25-2011 |
| 20110206662 | ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer. | 08-25-2011 |
| 20110201593 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - The invention provides novel compounds of formula I having the general formula: | 08-18-2011 |
| 20110200602 | ANTIBODIES TO EGFL7 AND METHODS FOR THEIR USE - The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies. | 08-18-2011 |
| 20110200596 | MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS - The invention provides methods and compositions comprising a novel stabilized monovalent antibody fragment. | 08-18-2011 |
| 20110200579 | NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO - The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO57290 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as cardiovascular, endothelial or angiogenic disorders; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; or developmental abnormalities. | 08-18-2011 |
| 20110191865 | Novel Gene Disruptions, Compositions and Methods Relating Thereto - The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO227, PRO233, PRO238, PRO1328, PRO4342, PRO7423, PRO10096, PRO21384, PRO353 or PRO1885 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities. | 08-04-2011 |
| 20110183938 | 1,7-DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 07-28-2011 |
| 20110183916 | Apo-2 Ligand - A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided. | 07-28-2011 |
| 20110177058 | METHODS AND COMPOSITIONS FOR MODULATING HGF/MET - The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF β chain to c-met. | 07-21-2011 |
| 20110172216 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 07-14-2011 |
| 20110171238 | NOVEL STRA6 POLYPEPTIDES - The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 07-14-2011 |
| 20110165157 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS - The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab. | 07-07-2011 |
| 20110165155 | METHODS OF TREATING METASTATIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 - Methods of treating patients having metastatic or unresectable locally advanced HER2 positive cancer, e.g., breast cancer, with the antibody-drug conjugate trastuzumab-MCC-DM1 are provided, wherein the patients have received extensive prior treatment, e.g., with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. | 07-07-2011 |
| 20110160221 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer. | 06-30-2011 |
| 20110159608 | GENETIC POLYMORPHISMS IN AGE-RELATED MACULAR DEGENERATION - The application relates to methods for determining whether a patient is at increased risk of developing wet AMD or whether a patient has an increased likelihood of benefiting from treatment with a high-affinity anti-VEGF antibody. | 06-30-2011 |
| 20110159009 | ANTI-VEGF ANTIBODIES - The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies. | 06-30-2011 |
| 20110158990 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE - The invention relates to a method of inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal comprising administering to said mammal a therapeutically effective amount of an imidazopyridine of formula I with anti-hyperproliferative activity. | 06-30-2011 |
| 20110155605 | Apo-2 ligand - A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided. | 06-30-2011 |
| 20110150865 | ANTIBODIES TO LYMPHOTOXIN-ALPHA - The invention provides various antibodies that bind to lymphotoxin-α, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies. | 06-23-2011 |
| 20110142859 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR - Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided. | 06-16-2011 |
| 20110142852 | MULTISPECIFIC ANTIBODIES - The invention provides multispecific antibodies and methods of making and using such antibodies. | 06-16-2011 |
| 20110135667 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 06-09-2011 |
| 20110130406 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS - Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 06-02-2011 |
| 20110130363 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 06-02-2011 |
| 20110124622 | ISOINDOLONES DERIVATIVES AS MEK KINASE INHIBITORS AND METHODS OF USE - The invention relates to isoindolones of formula, (I) with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 05-26-2011 |
| 20110123531 | COMBINATION THERAPY - The invention provides for the treatment of diseases or disorders characterized by cells expressing the CD40 membrane glycoprotein. The invention provides methods for the treatment of various diseases or disorders characterized by cells expressing CD40 with a combination of an agent causes the depletion of cells expressing CD40 and a second agent which causes the depletion of cells expressing the CD20 membrane antigen. Pharmaceutical compositions and articles of manufacture such as kits comprising the agents and combinations thereof are also provided. | 05-26-2011 |
| 20110123494 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 05-26-2011 |
| 20110117097 | HER2 ANTIBODY COMPOSITION - A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed. | 05-19-2011 |
| 20110117083 | BIOLOGICAL MARKERS FOR MONITORING PATIENT RESPONSE TO VEGF ANTAGONISTS - The invention provides methods and compositions to detect expression of one or more biomarkers for monitoring the effectiveness of treatment of with VEGF antagonists. The invention also provides methods for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods. | 05-19-2011 |
| 20110112279 | Compositions and Methods Relating to STOP-1 - The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein. | 05-12-2011 |
| 20110112085 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 05-12-2011 |
| 20110111408 | METHODS AND COMPOSITION FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES - The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof. | 05-12-2011 |
| 20110110942 | METHOD OF PROMOTING DENDRITIC SPINE DENSITY - The invention relates to methods of increasing density of dendritic spines as a means to retain or improve cognition and to treat disorders associated with decreased dendritic spine morphology and a psychiatric disorder such as addiction and schizophrenia or a disorder associated with impaired cognition such as autism, Lett Syndrome, Tourette Syndrome, and Fragile-X Syndrome. | 05-12-2011 |
| 20110110852 | Multivalent Antibodies and Uses Therefor - The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies. | 05-12-2011 |
| 20110104184 | ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS OF USE THEREOF - Disclosed are antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Also disclosed are methods of using such antibodies to reduce cancer cell tissue factor activity and to detect cancer cells that express TF. | 05-05-2011 |
| 20110104170 | NOVEL COMPOSITION AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES - The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 05-05-2011 |
| 20110098449 | MODULATORS OF HEPATOCYTE GROWTH FACTOR ACTIVATOR - The invention provides methods and compositions for modulating hepatocyte growth factor activator function. | 04-28-2011 |
| 20110097330 | Novel Gene Disruptions, Compostitions and Methods Relating Thereto - The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO179, PRO181, PRO244, PRO247, PRO269, PRO293, PRO298, PRO339, PRO341, PRO347, PRO531, PRO537, PRO718, PRO773, PRO860, PRO871, PRO872, PRO813, PRO828, PRO1100, PRO1114, PRO115, PRO1126, PRO1133, PRO1154, PRO1185, PRO1194, PRO1287, PRO1291, PRO1293, PRO1310, PRO1312, PRO1335, PRO1339, PRO2155, PRO1356, PRO1385, PRO1412, PRO1487, PRO1758, PRO1779, PRO1785, PRO1889, PRO90318, PRO3434, PRO3579, PRO4322, PRO4343, PRO4347, PRO4403, PRO4976, PRO260, PRO6014, PRO6027, PRO6181, PRO6714, PRO9922, PRO7179, PRO7476, PRO9824, PRO19814, PRO19836, PRO20088, PRO70789, PRO50298, PRO51592, PRO1757, PRO4421, PRO9903, PRO1106, PRO1411, PRO1486, PRO1565, PRO4399 or PRO4404 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities. | 04-28-2011 |
| 20110097325 | Modulation of T cell Differentiation for the treatment of T helper cell mediated diseases - The present invention relates to methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in either the Th1 subtype or the Th2 subtype, based on the relative expression levels of the gene TCCR, and its agonists or antagonists. The present invention further relates to a method of diagnosing Th1- and Th2-mediated diseases. | 04-28-2011 |
| 20110092479 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 04-21-2011 |
| 20110091477 | MODULATORS OF HEPATOCYTE GROWTH FACTOR ACTIVATOR - The invention provides methods and compositions for modulating hepatocyte growth factor activator function. | 04-21-2011 |
| 20110086841 | N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention relates to compounds of Formula I: | 04-14-2011 |
| 20110086840 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention relates to compounds of Formula I: | 04-14-2011 |
| 20110086837 | COMBINATIONS OF A PI3K INHIBITOR AND A MEK INHIBITOR - The invention relates methods of treating a patient with locally advanced or metastatic solid tumors with a combination of an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase or PI3K) and an inhibitor of mitogen activated protein kinase (MEK) described herein. | 04-14-2011 |
| 20110086032 | ANTI-FGF19 ANTIBODIES AND METHODS USING SAME - The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4. | 04-14-2011 |
| 20110081342 | ANTI-VEGF ANTIBODIES - Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. | 04-07-2011 |
| 20110077265 | INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds having the general formula U1-M-U2 wherein M is a linking group covalently joining R2, R3, R4 or R5 of U1 to an R2, R3, R4 or R5 group of U2; U1 and U2 have the general formula (I) and G, X1, X2, R2, R3, R3′, R4, R4′ and R5, are as described herein. | 03-31-2011 |
| 20110076273 | Highly Concentrated Pharmaceutical Formulations - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided. | 03-31-2011 |
| 20110076271 | DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER - Disclosed herein are methods and compositions useful for the diagnosis and treatment of angiogenic disorders, including, e.g., cancer. | 03-31-2011 |
| 20110064670 | METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER AGENT - The invention provides methods for identifying patients having an increased likelihood of responding to an anti-cancer agent or an increased likelihood of undergoing metastasis. The invention also provides methods for monitoring a patients' response to an anti-cancer agent. The invention also provides kits and articles of manufacture for use in the methods. | 03-17-2011 |
| 20110059112 | ANTI-ROBO4 ANTIBODIES AND USES THEREFOR - The invention provides anti-Robo4 antibodies, and compositions comprising the antibodies and methods of using these antibodies, including diagnostic and therapeutic methods. | 03-10-2011 |
| 20110059104 | Apo-2L receptor agonist and CPT-11 synergism - Methods of using effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells are provided. | 03-10-2011 |
| 20110059013 | ANTI-ROBO4 ANTIBODIES AND USES THEREFOR - The invention provides anti-Robo4 antibodies, and compositions comprising the antibodies and methods of using these antibodies, including diagnostic and therapeutic methods. | 03-10-2011 |
| 20110052576 | VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS - Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy. | 03-03-2011 |
| 20110052575 | ANTI-VEGF ANTIBODIES - Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. | 03-03-2011 |
| 20110052488 | Methods For Treating, Diagnosing, and Monitoring Rheumatoid Arthritis - Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents. | 03-03-2011 |
| 20110047103 | ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF PREVIOUSLY TREATED BREAST CANCER - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, in combination with one or more additional anti-tumor therapeutic agents in previously treated metastatic breast cancer. | 02-24-2011 |
| 20110046066 | INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I), and G, X | 02-24-2011 |
| 20110044977 | Subcutaneous anti-HER2 antibody formulations and uses thereof - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided. | 02-24-2011 |
| 20110039324 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS - The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same. | 02-17-2011 |
| 20110028688 | CRYSTAL STRUCTURE OF OX40L AND OX40L COMPLEXED WITH OX40 RECEPTOR - The present disclosure provides crystals of and structural coordinates of mOX40L, hOX40L, hOX40 receptor and complexes thereof. The crystals and crystal structures are useful, for example, in the design and synthesis of modulators of mOX40L, hOX40L, and/or hOX40 receptor. | 02-03-2011 |
| 20110028348 | BINDING POLYPEPTIDES WITH OPTIMIZED SCAFFOLDS - The invention provides variant heavy chain variable domains (VH) with increased folding stability. Libraries comprising a plurality of these polypeptides are also provided. In addition, compositions and methods of generating and using these polypeptides and libraries are provided. | 02-03-2011 |
| 20110020346 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 01-27-2011 |
| 20110020322 | CRYSTALLIZATION OF ANTI-CD20 ANTIBODIES - The present invention relates generally to crystalline forms of anti-CD20 antibodies and purification of anti-CD20 antibodies involving crystallization. | 01-27-2011 |
| 20110020300 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF GLUCOCORTICOID RECEPTOR (GCR) GENES - This invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a GCR gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a GCR gene using said pharmaceutical composition; and methods for inhibiting the expression of GCR in a cell. | 01-27-2011 |
| 20110015204 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer. | 01-20-2011 |
| 20110014198 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 01-20-2011 |
| 20110012894 | CRYSTAL STRUCTURE OF THE COMPLEX OF HEPATOCYTE GROWTH FACTOR BETA CHAIN WITH MET RECEPTOR AND METHODS OF USE - The disclosure provides a crystal structure of a complex of the HGF β-chain with am extracellular fragment of the Met receptor, as well as use of the crystal structure in the design, identification, and selection of ligands that modulate the Met Receptor and the interaction of HGF with the Met receptor. | 01-20-2011 |
| 20110009599 | APO-2 RECEPTOR POLYPEPTIDES - Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided. | 01-13-2011 |
| 20110008354 | ANTIBODIES TO APO-2 RECEPTOR POLYPEPTIDES - Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided. | 01-13-2011 |
| 20110008338 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 01-13-2011 |
| 20110008336 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 01-13-2011 |
| 20110008250 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 01-13-2011 |
| 20100331305 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR). | 12-30-2010 |
| 20100331251 | POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1 - The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue. | 12-30-2010 |
| 20100330096 | METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES - The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample. | 12-30-2010 |
| 20100330083 | PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS - A solution is provided comprising about 0.01-0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline. Such solution is useful for delivery from a catheter and for treating a thrombotic disorder by exposing fibrin-rich fluid from the disorder to an effective amount thereof, as well as in kits. In a preferred embodiment, peripheral thrombosis is treated in a mammal comprising delivering to the mammal via a catheter an effective amount of this solution. | 12-30-2010 |
| 20100330082 | NLRR-1 ANTAGONISTS AND USES THEREOF - NLRR-1 antagonists and methods of their use in treating cancer and other disorders are provided. | 12-30-2010 |
| 20100322946 | MULTISPECIFIC ANTIBODIES - The invention provides multispecific antibodies and methods of making and using such antibodies. | 12-23-2010 |
| 20100317643 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS - The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R | 12-16-2010 |
| 20100316652 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS - The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization. | 12-16-2010 |
| 20100316639 | BIOMARKERS FOR IGF-1R INHIBITOR THERAPY - The invention concerns the identification and validation of certain biomarkers for selecting patients for therapy with an IGF-1R inhibitor, particularly for breast and colorectal cancer. | 12-16-2010 |
| 20100316633 | INHIBITION OF ANGIOGENESIS - The present invention relates generally to the inhibition of inflammatory cell-mediated angiogenesis. In particular, the invention concerns the prevention or treatment of tumor angiogenesis, and the inhibition of tumor development, using Bv8 antagonists, such as anti-Bv8 antibodies. | 12-16-2010 |
| 20100303810 | METHOD FOR TREATING LUPUS - A method of treating lupus in a subject eligible for treatment is provided involving administering an effective amount of an antibody that binds to a B-cell surface marker to the subject to provide an initial exposure and a subsequent exposure to the antibody within certain dosing regimens and an article of manufacture therefor. | 12-02-2010 |
| 20100292312 | ANTI-DLL4 ANTIBODIES AND METHODS USING SAME - The invention provides anti-DLL4 antibodies, and compositions comprising and methods of using these antibodies. | 11-18-2010 |
| 20100291114 | Crystal structures and methods using same - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of FGFR3 function, and the identification and uses of said modulators. | 11-18-2010 |
| 20100285009 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 11-11-2010 |
| 20100280227 | POLYPEPTIDES THAT BIND BR3 AND USES THEREOF - The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of the BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods. | 11-04-2010 |
| 20100279298 | Methods and Compositions For Detecting Autoimmune Disorders - The invention provides methods and compositions useful for detecting autoimmune disorders. | 11-04-2010 |
| 20100278842 | ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME - The invention provides anti-EphB2 antibodies, immunoconjugates, and compositions comprising and methods of using these antibodies and immunoconjugates. | 11-04-2010 |
| 20100273257 | Apo-2DcR - Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided. | 10-28-2010 |
| 20100272738 | ANTI-OX40L ANTIBODIES AND METHODS USING SAME - The invention provides anti-OX40L antibodies, and compositions comprising and methods of using these antibodies. | 10-28-2010 |
| 20100267050 | METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN - Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided. | 10-21-2010 |
| 20100267033 | Methods and Compositions For Detecting Autoimmune Disorders - The invention provides methods and compositions useful for detecting autoimmune disorders. | 10-21-2010 |
| 20100266698 | USE OF INSULIN FOR THE TREATMENT OF CARTILAGINOUS DISORDERS - The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the administration of insulin and/or insulin variants. Optionally, the administration may be in combination with a cartilage agent (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor), in an extended- or sustained-release form. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of insulin and/or insulin in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of chondrocytes previously treated with an effective amount of insulin and/or insulin variant. | 10-21-2010 |
| 20100266593 | WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS - The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer. | 10-21-2010 |
| 20100261888 | Recombinant Production of Heparin Binding Proteins - A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate. | 10-14-2010 |
| 20100260782 | NOVEL ANTI- Alpha 5 Beta 1 ANTIBODIES AND USES THEREOF - The present invention provides new anti-α5β1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies. | 10-14-2010 |
| 20100255515 | ELISA FOR VEGF - The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index. | 10-07-2010 |
| 20100255010 | ANTI-HER ANTIBODIES - The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists. | 10-07-2010 |
| 20100247531 | ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME - The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies. | 09-30-2010 |
| 20100239568 | DIAGNOSTICS AND TREATMENTS FOR TUMORS - Methods for the treatment of cancer with combination therapies that include anti-VEGF antibodies are provided. Methods for diagnosing resistant tumors are also provided. | 09-23-2010 |
| 20100239567 | Antibody Formulation - A formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.5 to about 6.5, and an optional surfactant is described, along with uses for such a formulation. | 09-23-2010 |
| 20100234576 | HUMAN TOLL HOMOLOGUES - The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein. | 09-16-2010 |
| 20100233153 | NOVEL GENE DISRUPTIONS, COMPOSITIONS AND THE METHODS RELATING THERETO - The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO1105, PRO1279 or PRO1783 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities. | 09-16-2010 |
| 20100233121 | METHOD FOR TREATING MULTIPLE SCLEROSIS - Methods for treating multiple sclerosis (MS) with a CD20 antibody using special dosing regimens and protocols are described. Articles of manufacture for use in such methods are also described. | 09-16-2010 |
| 20100226880 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 09-09-2010 |
| 20100221262 | ANTI-UNC5B ANTIBODIES AND METHODS OF USE - The invention provides anti-Unc5B antibodies, compositions and kits comprising the antibodies and methods of making and using the antibodies. The present invention also relates to use of anti-Unc5B antibodies to modulate angiogenesis and to treat or prevent disorders associated with abnormal angiogenesis. | 09-02-2010 |
| 20100216115 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS - Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer. | 08-26-2010 |
| 20100215669 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 08-26-2010 |
| 20100210826 | HGF BETA CHAIN VARIANTS - The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators. | 08-19-2010 |
| 20100209956 | METHODS AND COMPOSITIONS FOR MODULATING HEPATOCYTE GROWTH FACTOR ACTIVATION - The invention provides methods and compositions for modulating hepsin activity and the HGF/c-met signaling pathway, in particular by regulating pro-HGF activation by hepsin. | 08-19-2010 |
| 20100203056 | ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION - The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity. | 08-12-2010 |
| 20100203041 | ANTIBODIES TO EGFL7 AND METHODS FOR THEIR USE - The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies. | 08-12-2010 |
| 20100189719 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 07-29-2010 |
| 20100189660 | METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEIN - Sensitive, non-radioactive fatty-acyls of Formula I are useful in in vivo methods for detection and cellular imaging of a fatty-acylated substrate (e.g., protein or polypeptide). | 07-29-2010 |
| 20100166749 | Polypeptide variants with altered effector function - The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof. | 07-01-2010 |
| 20100166741 | ALTERED BR-3 BINDING POLYPEPTIDES - The present invention relates to novel BR3 binding antibodies having altered Fc effector function and/or having a mature core carbohydrate structure in the Fc region which lacks fiicose. The present invention also relates to the use of those BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods. | 07-01-2010 |
| 20100158898 | METHODS OF TREATING IgE-MEDIATED DISORDERS COMPRISING THE ADMINISTRATION OF HIGH CONCENTRATION ANTI-IgE ANTIBODY FORMULATIONS - The present application relates to methods of treating IgE-mediated disorders comprising the administration of highly concentrated anti-IgE antibody formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. | 06-24-2010 |
| 20100158856 | Assays and methods using biomarkers - Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided. | 06-24-2010 |
| 20100145027 | Compositions and Methods for the Diagnosis and Treatment of Tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 06-10-2010 |
| 20100143352 | COMBINATION THERAPY FOR B CELL DISORDERS - The invention provides methods of treating B cell based malignancies and B-cell regulated autoimmune disorders using a combination therapy of anti-CD20 antibody with a BLyS antagonist. | 06-10-2010 |
| 20100143351 | Anti-Angiogenesis Therapy for the Treatment of Breast Cancer - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human subjects susceptible to or diagnosed with breast cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 06-10-2010 |
| 20100136624 | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method - A method of making monoclonal antibodies according to a mixed antigen immunization protocol is described. In addition, antibodies obtainable by the method are disclosed which specifically cross-react with two or more different receptors to which Apo-2 ligand (Apo-2L) can bind. | 06-03-2010 |
| 20100136580 | DISHEVELED PDZ MODULATORS - The invention provides modulators of Dvl PDZ-ligand interaction, and methods of identifying and using these modulators. | 06-03-2010 |
| 20100136005 | Method of Treatment Using Humanized Anti-CD11a Antibodies - Humanized anti-CD11 | 06-03-2010 |
| 20100130539 | IMIDAZOPYRIDINE INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein Q, X | 05-27-2010 |
| 20100129381 | ANTI-FGF19 ANTIBODIES AND METHODS USING SAME - The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4. | 05-27-2010 |
| 20100129375 | METHODS FOR INHIBITING OCULAR ANGIOGENESIS - The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders. | 05-27-2010 |
| 20100129356 | COMPOSITIONS AND METHODS FOR MODULATING VASCULAR DEVELOPMENT - The present invention provides methods of using a DLL4 modulator to modulate vascular development. Furthermore, methods of treatment using DLL4 modulators, such as DLL4 antagonists, are provided. | 05-27-2010 |
| 20100119523 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS - The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization. | 05-13-2010 |
| 20100113350 | METHODS AND COMPOSITIONS FOR MODULATING PROSTASIN - The invention provides methods and compositions related to modulating prostasin. | 05-06-2010 |
| 20100111963 | METHOD FOR TREATING AGE-RELATED MACULAR DEGENERATION - A method is provided for administering to a mammal suffering from, or at risk for, age-related macular degeneration. | 05-06-2010 |
| 20100099101 | METHODS FOR TREATING, DIAGNOSING, AND MONITORING LUPUS - Methods of identifying, diagnosing, and prognosing lupus, including certain subphenotypes of lupus, are provided, as well as methods of treating lupus, including certain subpopulations of patients. Also provided are methods for identifying effective lupus therapeutic agents and predicting responsiveness to lupus therapeutic agents. | 04-22-2010 |
